NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Published on November 16, 2010
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
Commission
File Number 333-119366
NOTIFICATION
OF LATE FILING
|
¨ Form
10-K
|
¨ Form
11-K
|
¨ Form
20-F
|
x Form
10-Q
|
¨ Form N-SAR
For
Period Ended: September 30, 2010
|
o Transition Report
on Form 10-K
|
o Transition Report
on Form 10-Q
|
|
o Transition Report
on Form 20-F
|
o Transition Report
on Form N-SAR
|
For the
Transition Period Ended: _______________________________________
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
item(s) to which the notification
relates:
_______________________________
PART
I
|
Full
name of registrant
|
Novelos
Therapeutics, Inc.
|
|
Former
name if applicable
|
|
|
Address
of principal executive office
|
One
Gateway Center, Suite 504
|
|
City,
state and zip code
|
Newton,
Massachusetts 02458
|
PART
II
RULE
12b-25 (b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25 (b), the following should be
completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
|
x
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before
the 15
th calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or
the transition report portion thereof could not be filed within the prescribed
time period.
The
information necessary for the timely filing of the registrant’s Form 10-Q for
the quarterly period ended September 30, 2010 could not be compiled and
processed without undue hardship and expense to the registrant. The
registrant undertakes the responsibility to file such quarterly report no
later than five days after its original due date.
PART
IV
OTHER
INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification
|
Harry
S. Palmin
|
(617)
244-1616
|
|
(Name)
|
(Telephone
Number)
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If the answer is no,
identify report(s).
T
Yes ¨ No
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof?
¨
Yes T
No
If so:
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Novelos
Therapeutics, Inc.
Name
of Registrant as Specified in Charter
Has
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date:
November 16, 2010
|
By:
|
/s/
Harry S. Palmin
|
|
|
Harry
S. Palmin
|
|||
|
President
and Chief Executive Officer
|
|||